Search

Razelle Kurzrock

from San Diego, CA
Age ~70
Get Report
Also known as:
Raezel K Kurzrock, Razell Kurzrock
Phone and address:
10991 Twinleaf Ct, San Diego, CA 92131
Related to:
Laura A Cohen, 73Rena Cohen KurzrockBenjamin Kurzrock, 35Philip R Cohen, 66Benjamin A Cohen, 35
Connected to:
Gabrielle E Kurzrock, 37Joan L Kurzrock, 67Daniel Kurzweil, 34Daniele Kurzweil, 41Dorothy P Kurzweil, 89Jack H Kurzweil, 86Kathryn J Kurzweil, 67Morton E Kurzweil, 95Paul E Kurzweil, 59Phillip W Kurzyna, 51

Razelle Kurzrock Phones & Addresses

  • 10991 Twinleaf Ct, San Diego, CA 92131
  • Philadelphia, PA
  • 805 Anderson St, Bellaire, TX 77401 (713) 667-8343
  • Houston, TX

Work

Company: MD Anderson Cancer Center Address: 1515 Holcombe Blvd Suite 207, Houston, TX 77030 Phones: (713) 792-2121

Education

School / High School: UNIVERSITY OF TORONTO / COLLEGE OF MEDICINE

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Hematology, 1994

Specialities

Hematology • Medical Oncology • Oncology

Professional Records

Medicine Doctors

Razelle Kurzrock Photo 1

Dr. Razelle Kurzrock, Houston TX - MD (Doctor of Medicine)

View page
Specialties:
Hematology
Medical Oncology
Oncology
Address:
1515 Holcombe Blvd, Houston, TX 77030

1515 Holcombe Blvd Suite 207, Houston, TX 77030

MD Anderson Cancer Center
1515 Holcombe Blvd Suite 207, Houston, TX 77030
(713) 792-2121 (Phone)
Certifications:
Hematology, 1994
Internal Medicine, 1983
Medical Oncology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1515 Holcombe Blvd, Houston, TX 77030

1515 Holcombe Blvd Suite 207, Houston, TX 77030

MD Anderson Cancer Center
1515 Holcombe Blvd Suite 207, Houston, TX 77030

Montefiore Medical Center
111 East 210Th Street, Bronx, NY 10467

Saint Joseph's Medical Center
127 South Broadway, Yonkers, NY 10701
Education:
Medical School
UNIVERSITY OF TORONTO / COLLEGE OF MEDICINE
Medical School
Mt Sinai Hosp
Medical School
Tulane U Affil Hosp
Medical School
MD Anderson Hosp
Razelle Kurzrock Photo 2

Razelle Kurzrock, Houston TX

Work:
M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030
Razelle Kurzrock Photo 3

Razelle Kurzrock, Houston TX

View page
Specialties:
Internist
Address:
1515 Holcombe Blvd, Houston, TX 77030
Education:
University of Toronto, Faculty of Medicine - Doctor of Medicine
Tulane University Hospital & Clinic - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Razelle Kurzrock
Razelle Kurzrock MD
Internist
1515 Holcombe Blvd, Houston, TX 77030
(713) 792-6161

Publications

Isbn (Books And Publications)

Molecular Biology in Cancer Medicine

View page
Author

Razelle Kurzrock

ISBN #

0195211731

Biological Response Modifiers in the Treatment of Hematopoietic Neoplasia

View page
Author

Razelle Kurzrock

ISBN #

0824786270

Cytokines: Interleukins and Their Receptors

View page
Author

Razelle Kurzrock

ISBN #

0792336364

Us Patents

Liposomal Curcumin For Treatment Of Cancer

View page
US Patent:
20060067998, Mar 30, 2006
Filed:
Sep 7, 2005
Appl. No.:
11/221179
Inventors:
Razelle Kurzrock - Bellaire TX, US
Lan Li - Houston TX, US
Kapil Mehta - Bellaire TX, US
Bharat Aggarawal - Houston TX, US
International Classification:
A61K 9/127
A61K 31/12
US Classification:
424450000, 514688000
Abstract:
The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.

Liposomal Curcumin For Treatment Of Neurofibromatosis

View page
US Patent:
20080103213, May 1, 2008
Filed:
Oct 5, 2007
Appl. No.:
11/868251
Inventors:
RAZELLE KURZROCK - HOUSTON TX, US
LAN LI - HOUSTON TX, US
KAPIL MEHTA - HOUSTON TX, US
BHARAT AGGARWAL - HOUSTON TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
A61K 31/12
A61P 25/00
US Classification:
514679000
Abstract:
The present invention provides a compositions and methods for the treatment of Neurofibromatosis Type 1 and 2, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system to target Merlin and proteins of the Merlin pathway. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.

Liposomal Curcumin For Treatment Of Diseases

View page
US Patent:
20080138400, Jun 12, 2008
Filed:
Dec 1, 2007
Appl. No.:
11/949027
Inventors:
RAZELLE KURZROCK - Bellaire TX, US
LAN LI - HOUSTON TX, US
KAPIL MEHTA - Bellaire TX, US
BHARAT BHUSHAN AGGARAWAL - HOUSTON TX, US
LAWRENCE HELSON - Quakertown PA, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
A61K 9/127
A61K 31/12
A61P 35/04
A61P 29/00
A61P 37/00
A61P 25/00
A61P 19/00
A61P 1/00
US Classification:
424450, 514679
Abstract:
The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.

Methods And Compositions Using Chelator-Antibody Conjugates

View page
US Patent:
20100104511, Apr 29, 2010
Filed:
Nov 14, 2007
Appl. No.:
12/516172
Inventors:
Razelle Kurzrock - Bellaire TX, US
Jing Gong - Manvel TX, US
David Yang - Sugar Land TX, US
Saady Kohanim - Sugar Land TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
A61K 51/00
C07K 16/00
A61P 35/04
A61P 29/00
US Classification:
424 153, 5303911, 5303913
Abstract:
Disclosed are pharmaceutical compositions that include a chelator and an antibody directed against a phosphorylation site of a protein, wherein the antibody is conjugated to the chelator to form a chelator-antibody conjugate. For example, the antibody may recognize a phosphorylated tyrosine residue or a phosphorylated serine residue of a cell surface receptor. Also disclosed are methods of synthesizing a radiolabeled chelator-antibody conjugate, wherein the antibody is directed against a phosphorylation site of a protein. Also disclosed are methods for imaging a site in a subject that involve administering to the subject an effective amount of a composition that includes a valent metal ion-labeled chelator-antibody conjugate, wherein the antibody is an antibody directed against a phosphorylation site of a protein, and detecting a radioactive signal from the site in the subject following administration of an effective amount of the composition. The method of imaging can be applied in diagnosing a tumor, such as a tumor that can be responsive to therapy using a tyrosine kinase inhibitor, and in the treatment of a tumor, such as by targeting therapy to cell surface receptors that include phosphorylation sites.

Liposomal Curcumin For Treatment Of Cancer

View page
US Patent:
20110287085, Nov 24, 2011
Filed:
May 27, 2011
Appl. No.:
13/117807
Inventors:
Razelle Kurzrock - Houston TX, US
Lan Li - Houston TX, US
Kapil Mehta - Houston TX, US
Bharat B. Aggarwal - Houston TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
A61K 9/14
A61P 35/00
A61K 9/51
A61K 9/19
A61K 31/12
A61K 9/127
US Classification:
424450, 424489, 514679, 424501, 424451
Abstract:
The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.

Process For Measuring Tumor Response To An Initial Oncology Treatment

View page
US Patent:
20170251973, Sep 7, 2017
Filed:
Mar 1, 2016
Appl. No.:
15/057965
Inventors:
Razelle Kurzrock - San Diego CA, US
Assignee:
Novena Therapeutics Inc. - San Diego CA
International Classification:
A61B 5/00
C12Q 1/68
A61B 6/03
Abstract:
There is disclosed a process for determining early patient response to an initial therapy administration, comprising a rapid determination of effectiveness of a therapy after an initial treatment for a cancer indication. More specifically, the rapid determination of effectiveness is made days following initial therapy. There is further disclosed a process for determining early patient response to an initial cancer treatment, comprising (a) conducting a baseline PET FDG or PET FLT scan of the tumor region in a patient by determining tumor tissue metabolic rate and/or apoptotic rate (for FLT), (b) providing a single potentially effective dose of a therapeutic to the patient, (c) conducting a second PET FDG or PET FLT scan by determining tumor tissue metabolic rate, and (d) comparing the results of the first PET scan to the second PET scan to determine an imaging response in the PET scan results whereby at least a 1% reduction in tumor tissue metabolic rate indicates that the patient would benefit to treat the tumor with the initial cancer treatment. Preferably, in addition to the PET scans conducted before and after an initial dose of a cancer drug, the present disclosure further provides parallel before and after measurement(s) of the level of circulating tumor DNA (ctDNA) for specific oncogene mutations/alterations to identify early patient response to drug therapy.
Control profile
Razelle Kurzrock from San Diego, CA, age ~70 Get Report